SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Hematology/Oncology Consultation — Irène Joliot-Curie
| Patient | Irène Joliot-Curie |
|---|
| Date of birth | 1968-09-12 |
|---|
| Identifiers | MRN HR-RB003-SYN; SSN (made up) 000-03-8841 |
|---|
| Document date | 2026-09-16 |
|---|
| Author | Tobias Engquist-Mensah, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Pancytopenia with 12 percent blasts on the blood smear in a 58-year-old nuclear physicist with about four decades of occupational exposure to ionizing radiation and treated tuberculosis. Please confirm the diagnosis by bone marrow, classify it, assess her fitness, and plan treatment, transfusion and infection prevention. [S]
Urgency: Urgent, within two days; she is stable and afebrile today and has a written fever and bleeding plan. [S]
Questions for the consultant:
- Does she have acute leukemia, and is acute promyelocytic leukemia excluded?
- How should it be classified, given her occupational rather than therapeutic radiation exposure, and what genetic tests will set her risk?
- Is she fit for intensive induction, and if not, what treatment do you advise?
- What transfusion support and infection prophylaxis does she need, given her past tuberculosis?
- Is she a candidate for allogeneic stem cell transplant, and when should palliative care join her care?
- What should be done about her occupational exposure history and dose records?
History of Present Illness
Mrs. Joliot-Curie, a 58-year-old nuclear physicist, is seen at the request of Dr. Marchand-Ellis two days after pancytopenia with circulating blasts was found. She describes two months of tiredness, then bruising and gum bleeding, and in the last two days breathlessness on one flight of stairs. She has had no fever, bone pain, or weight loss. Her occupational history is long: X-ray work early in her career, decades of laboratory work with polonium and other radioactive sources, and the rupture of a sealed polonium source on her bench about ten years ago, she does not know what dose she received from it; her monitored doses are recorded by her employer. Pulmonary tuberculosis in her forties was treated to completion, and she has been breathless on stairs since. She has never smoked and takes no medicines. Her mother died of aplastic anemia attributed to radiation. She wants the evidence and the numbers, and wants to keep working with her mind for as long as she can. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Irène Curie was born in Paris on 12 September 1897, the elder daughter of the physicist Pierre Curie and his wife, a physicist who also worked with radioactive materials. [D]
- During the First World War she served as a nurse radiographer, operating X-ray machines in mobile field hospitals alongside her mother. [D]
- She became a Doctor of Science in 1925 with a thesis on the alpha rays of polonium, and in 1926 married Frédéric Joliot; the couple joined their surnames and worked together on natural and artificial radioactivity and nuclear physics. [D]
- In 1935 she and Frédéric Joliot shared the Nobel Prize in Chemistry for their synthesis of new radioactive elements, after showing that bombarding aluminum foil with alpha particles produced artificial radioactivity. [D]
- In 1936 she was appointed Undersecretary of State for Scientific Research; she became a professor in the Faculty of Science in Paris in 1937, and her research on the action of neutrons on heavy elements in 1938 was an important step toward the discovery of nuclear fission. [D]
- She and Frédéric Joliot had a daughter and a son. [D]
- She had always been of unstable health, and the couple took regular trips to the countryside to help her condition. [D]
- During the Second World War she spent time in Switzerland recovering from tuberculosis, and in 1944 brought her children with her to Switzerland. [D]
- In 1946 she became director of the Radium Institute; as a commissioner for atomic energy for six years she took part in building the first French atomic pile in 1948, and she drew up the plans for the large nuclear physics center at Orsay. [D]
- In 1946 a capsule of polonium exploded on her laboratory bench. [D]
- Shortly after 1950 her health declined visibly. [D]
- Her mother died on 4 July 1934; the director of the sanatorium where she died reported an aplastic pernicious anemia of rapid, feverish development, in which the bone marrow did not react, probably because it had been injured by a long accumulation of radiations. [D]
4 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review booked | resolved | confirmed |
D61.818 | S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D). |
| Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemia | active | confirmed |
C92.00 | S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented. |
| Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years ago | active | confirmed |
Z57.1 | S — Synthetic modern coding of her documented occupational exposure. |
| Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active disease | active | confirmed |
Z86.11 | S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic. |
Physical Exam
Vital signs recorded on 2026-09-16; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Pale and tired but alert; weight 53.8 kg |
| Skin | Bruises on the thighs and shins; petechiae on the lower legs |
| Mouth | Gum petechiae; no gum infiltration |
| Lymph nodes | None enlarged |
| Respiratory | Fine crackles at the right apex |
| Abdomen | No enlarged liver or spleen |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-09-16 | Leukocytes [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-09-16 | Neutrophils [#/volume] in Blood by Automated count | 0.5 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 2026-09-16 | Hemoglobin [Mass/volume] in Blood | 7.1 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-09-16 | Platelets [#/volume] in Blood by Automated count | 22 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-09-16 | Blasts/Leukocytes in Blood by Manual count | 14 | % | None seen normally | High | S |
| 2026-09-16 | Blasts/cells in Bone marrow | 34 | % | Below 5% normally; 20% or more defines AML | High | S |
| 2026-09-16 | INR in Platelet poor plasma by Coagulation assay | 1.1 | {INR} | 0.8-1.2 | Normal | S |
| 2026-09-16 | Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay | 310 | mg/dL | 200-400 mg/dL | Normal | S |
Assessment
- Acute myeloid leukemia (C92.00). Confirmed: 34 percent marrow myeloblasts of myeloid phenotype. Acute promyelocytic leukemia is excluded by the phenotype, the normal coagulation tests and the negative rapid PML::RARA test, so there is no need for emergency all-trans retinoic acid. The multilineage dysplasia and the macrocytosis suggest a leukemia arising from a damaged marrow. Classification and risk await the cytogenetics and molecular panel. After long exposure to ionizing radiation, the most likely findings are a complex karyotype, loss of 5q or 7, and a TP53 mutation, which would mean adverse risk. The WHO and ICC labels for leukemia after cytotoxic therapy (therapy-related) are defined by earlier chemotherapy or radiotherapy given as treatment, so her leukemia should be classified by its genetics and her occupational exposure recorded in the history rather than as a therapy-related label. [S]
- Past tuberculosis and fitness (Z86.11). ECOG 1 today, but her lung reserve may be reduced by old tuberculous scarring; lung function with diffusing capacity, an echocardiogram and an ECG are needed before choosing induction. If her diffusing capacity is 65 percent of predicted or less, or her performance status falls to 2, she would be outside the trial definition of fitness for intensive induction. The chest X-ray shows no active tuberculosis; treated disease needs no preventive therapy, but new respiratory symptoms during neutropenia should be investigated promptly. [S]
- Occupational exposure to ionizing radiation (Z57.1). A recognized risk factor for myeloid leukemia, consistent with her history. Her employer must keep her dose records and give them to her on request. [S]
Data reviewed: Dr. Marchand-Ellis's intake note and results. Today: white cells 1.9 with neutrophils 0.5 x10^3/uL, hemoglobin 7.1 g/dL, platelets 22 x10^3/uL, blasts 14 percent on the smear; INR 1.1, fibrinogen 310 mg/dL. Bone marrow aspirate this morning: 34 percent myeloblasts with dysplasia in the red cell and megakaryocyte lines; flow cytometry shows myeloid blasts positive for CD34, CD117, CD13, CD33, HLA-DR and MPO; rapid PML::RARA FISH negative. Cytogenetics and a myeloid next-generation sequencing panel are pending. Chest X-ray this morning: old fibrotic scarring at the right apex, no active disease. [S]
Plan of Treatment
- Cytogenetics, a myeloid sequencing panel (including FLT3, NPM1, IDH1, IDH2, TP53 and CEBPA) and FISH from today's marrow; classify by both WHO 2022 and ICC 2022 and assign ELN 2022 genetic risk when results are back, in about ten days. [S]
- Echocardiogram, ECG and lung function tests with diffusing capacity on the day of the results review. [S]
- If the genetics are adverse (for example TP53-mutated or complex karyotype) or she is unfit for intensive induction, azacitidine 75 mg/m2 on days 1 to 7 with venetoclax in 28-day cycles; if she is fit and the genetics are favorable or intermediate, intensive induction would be offered. Either way, discuss clinical trials. [S]
- With venetoclax, admit for the ramp-up with tumor lysis monitoring, allopurinol and fluids; with posaconazole, give venetoclax 70 mg daily after the ramp-up; marrow on day 21 to 28, holding venetoclax until counts recover if the marrow is clear. [S]
- Transfusion: irradiated, leukoreduced products; red cells one unit at a time for hemoglobin below 7 to 8 g/dL or symptoms (one unit today); platelets for a count below 10 x10^3/uL or bleeding; no platelet transfusion was needed for today's biopsy. [S]
- Prophylaxis once treatment starts: posaconazole (mold-active, because neutropenia will be prolonged), acyclovir, and levofloxacin while neutrophils are below 0.5; a written fever plan now. [S]
- Hepatitis B (surface antigen, core antibody, surface antibody), hepatitis C and HIV tests before therapy, and HLA typing now. [S]
- She is a potential candidate for a reduced-intensity allogeneic transplant in first remission, especially with adverse genetics: transplant center evaluation and an unrelated donor search at the start of treatment. [S]
- Specialist palliative care from the start of treatment, alongside it, for symptoms, prognosis and her goals. [S]
- Document the occupational history in full and request her dosimetry and bioassay records in writing from the employer's radiation safety office. [S]
- Discussed with Dr. Marchand-Ellis, who saw her the same day. The diagnosis and what the pending tests will decide were explained to Mrs. Joliot-Curie in plain terms with the numbers she asked for; she took notes and asked for the trial reports. [S]
- Follow-up: Results review in about ten days with Dr. Marchand-Ellis, with the genetics, echocardiogram and lung function tests, to decide induction; the hematology/oncology team will lead treatment and see her through each cycle. [S]